403 related articles for article (PubMed ID: 34862742)
1. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk A; Urbanska EM
CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
[TBL] [Abstract][Full Text] [Related]
2. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
3. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Németh H; Toldi J; Vécsei L
J Neural Transm Suppl; 2006; (70):285-304. PubMed ID: 17017544
[TBL] [Abstract][Full Text] [Related]
4. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
[TBL] [Abstract][Full Text] [Related]
5. Drosophila eye color mutants as therapeutic tools for Huntington disease.
Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
[TBL] [Abstract][Full Text] [Related]
6. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
8. Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease.
Sharma R; Razdan K; Bansal Y; Kuhad A
Expert Opin Ther Targets; 2018 Oct; 22(10):849-867. PubMed ID: 30223691
[TBL] [Abstract][Full Text] [Related]
9. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
10. Kynurenic Acid Restores Nrf2 Levels and Prevents Quinolinic Acid-Induced Toxicity in Rat Striatal Slices.
Ferreira FS; Biasibetti-Brendler H; Pierozan P; Schmitz F; Bertó CG; Prezzi CA; Manfredini V; Wyse ATS
Mol Neurobiol; 2018 Nov; 55(11):8538-8549. PubMed ID: 29564809
[TBL] [Abstract][Full Text] [Related]
11. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
[TBL] [Abstract][Full Text] [Related]
12. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine and its metabolites in Alzheimer's disease patients.
Gulaj E; Pawlak K; Bien B; Pawlak D
Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
[TBL] [Abstract][Full Text] [Related]
14. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Schwarz MJ; Guillemin GJ; Teipel SJ; Buerger K; Hampel H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):345-52. PubMed ID: 23192697
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
16. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
17. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
Guidetti P; Wu HQ; Schwarcz R
Exp Neurol; 2000 May; 163(1):123-30. PubMed ID: 10785450
[TBL] [Abstract][Full Text] [Related]
18. The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.
Behl T; Kaur I; Sehgal A; Singh S; Bhatia S; Al-Harrasi A; Zengin G; Bumbu AG; Andronie-Cioara FL; Nechifor AC; Gitea D; Bungau AF; Toma MM; Bungau SG
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201647
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.
Erhardt S; Olsson SK; Engberg G
CNS Drugs; 2009; 23(2):91-101. PubMed ID: 19173370
[TBL] [Abstract][Full Text] [Related]
20. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
